Role of phototherapy, systemic immunosuppressant medications, and biologic agents in the management of skin disease

Stepwise management

Management of moderate-severe inflammatory skin disease (psoriasis being the paradigm example) follows a stepwise escalation from topical therapy, through phototherapy, to systemic conventional immunosuppressants, and finally targeted biologic/small-molecule agents - matched to disease severity and response to prior treatment steps
A substantial proportion of patients with significant psoriasis or other severe inflammatory dermatoses require treatment beyond topical therapy alone, given inadequate response or extent of disease too great for topical management

Each treatment tier targets the underlying immune-mediated inflammatory process with increasing specificity/potency: phototherapy (broad local immunomodulation), conventional systemic agents (methotrexate, ciclosporin - broader systemic immunosuppression), and biologics (highly targeted cytokine blockade - TNF, IL-17, IL-23 inhibitors depending on the specific agent) - reflecting an increasingly refined understanding of the specific cytokine pathways driving diseases like psoriasis

Treatment escalation is generally guided by disease severity (e.g. body surface area affected, quality-of-life impact) and response to the preceding treatment tier, rather than a fixed universal sequence applied regardless of individual presentation

Biologic selection is increasingly individualised by specific disease phenotype and comorbidity (e.g. an IL-17 inhibitor may be favoured in a patient with concurrent psoriatic arthritis, while specific agents are avoided or used cautiously with certain comorbidities such as inflammatory bowel disease for some IL-17 inhibitors)
Pre-treatment screening (latent TB, hepatitis B/C - see pre-treatment screening for biological agents) applies equally before starting a biologic for skin disease as for any other indication

Psoriasis (the paradigm condition for this stepwise approach), psoriatic arthritis (relevant to biologic selection), atopic dermatitis (an expanding target for newer biologics - e.g. dupilumab), latent TB/hepatitis screening before biologics

Biologic therapy selection for skin disease increasingly considers the whole patient (comorbidities, concurrent joint disease) rather than skin severity alone - reflecting how precisely targeted modern agents allow individualised matching of mechanism to the patient's full clinical picture

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.